Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting
Multiplexed-engineered, iPSC-derived CAR T Cell Targets Proteins Expressed on Cancer Cells in Response to Cellular Stress and Malignant ...
Yahoo Finance25d
200+ Pharma Companies Vie for the Top Spot in the Expanding Antibody-Drug Conjugate Oncology Market | DelveInsight
The ADC oncology market is experiencing rapid growth, attracting over 200 pharmaceutical companies vying for leadership in this innovative therapeutic space. As competition intensifies, advancements ...